{"id":324,"date":"2020-06-29T07:14:40","date_gmt":"2020-06-29T07:14:40","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=324"},"modified":"2020-06-29T07:14:40","modified_gmt":"2020-06-29T07:14:40","slug":"28-june-2020-baricitinib-9-7-vs-1-3-discharge-rate-in-the-baricitinib-arm-compared-to-control-arm","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/28-june-2020-baricitinib-9-7-vs-1-3-discharge-rate-in-the-baricitinib-arm-compared-to-control-arm\/","title":{"rendered":"(28 June 2020) Baricitinib- 9.7% vs 1.3%, discharge rate in the baricitinib arm compared to control arm"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\">Retrospective, multicenter study on the impact of baricitinib in COVID-19 moderate pneumonia<\/p>\n<p>https:\/\/doi.org\/10.1016\/j.jinf.2020.06.052<\/p>\n<p class=\"\">113 patients were in the baricitinib-arm, and 78 in the control-arm. The<br \/>\nresults indicate that the 2-week case fatality rate was significantly lower in the baricitinib-arm compared with controls [0% (0\/113) vs 6.4% (5\/78) (p-value: 0.010; 95%CI 0.0000\u20130.4569)]. ICU admission was requested in 0.88% (1\/113) vs 17.9% (14\/78) patients in the baricitinib-arm compared to the control-arm (week 1, p-value: 0.019; 95%CI 0.0092-0.6818), (week<br \/>\n2, p-value: &lt;0.0001; 95%CI 0.0038\u20130.2624). Discharge rate was significantly higher in the baricitinib-arm at week 1 [9.7% (11\/113) vs 1.3% (1\/78) (p-value: 0.039; 95%CI: 1.41-90.71)], and at week 2 [77.8% (88\/113) vs 12.8% (10\/78) (p:&lt;0.0001; 95%CI 10.79\u201351.74)]. In conclusion, baricitinib is a promising and safe therapy in patients with moderate COVID-19 pneumonia.&nbsp;<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Retrospective, multicenter study on the impact of baricitinib in COVID-19 moderate pneumonia https:\/\/doi.org\/10.1016\/j.jinf.2020.06.052 113 patients were in the baricitinib-arm, and 78 in the control-arm. The results indicate that the 2-week case fatality rate was significantly lower in the baricitinib-arm compared&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/28-june-2020-baricitinib-9-7-vs-1-3-discharge-rate-in-the-baricitinib-arm-compared-to-control-arm\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(28 June 2020) Baricitinib- 9.7% vs 1.3%, discharge rate in the baricitinib arm compared to control arm&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[21,4],"tags":[45],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/324"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=324"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/324\/revisions"}],"predecessor-version":[{"id":325,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/324\/revisions\/325"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=324"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=324"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=324"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}